Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 46Sarcoma 21Neoplasms 18Neoplasm Metastasis 15Ovarian Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 8Recurrence 5Melanoma 5Fallopian Tube Neoplasms 5Thyroid Neoplasms 4Prostatic Neoplasms 4Liposarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Lung Neoplasms 3Leiomyosarcoma 3Kidney Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Ovarian Epithelial 3Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Refractory Solid Tumors 2Neuroendocrine Tumors 2Gliosarcoma 2Financial Stress 2Chondrosarcoma, Extraskeletal Myxoid 2

Interventions

Radiotherapy 83Temozolomide 78Filgrastim 34Carboplatin 33Vincristine 29Etoposide 26Cyclophosphamide 25Carmustine 25Irinotecan 23Chemotherapy, Adjuvant 23Cisplatin 21Peripheral Blood Stem Cell Transplantation 20Thiotepa 14Lomustine 14Granulocyte Colony-Stimulating Factor 13Surgical Procedures, Operative 12Procarbazine 12Bevacizumab 11Thalidomide 10O(6)-benzylguanine 10Drug Therapy 10etoposide phosphate 9Methotrexate 9Magnetic Resonance Spectroscopy 9Gene Expression Profiling 9Radiation 8Paclitaxel 8sargramostim 7Ifosfamide 7Everolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Central Nervous System Neoplasms × pazopanib × Clear all
NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
35 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

University of Illinois at Chicago

Phase 1 Completed
28 enrolled
BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡